Inizio Ignite Sparks a New Era of Connected Advisory Solutions
January 7, 2026 | Inizio Ignite
Inizio, a leading global commercialization partner for pharma and life sciences, today unveiled Inizio Ignite, a reimagined, fully integrated advisory partner designed to accelerate pharma performance through strategy, insights, and innovation.
Inizio Ignite brings together Research Partnership, Putnam, Vynamic, and STEM to address the growing complexity of today’s pharmaceutical environment. Purpose-built and AI-enabled, Inizio Ignite helps clients shape strategy, drive scalable transformation, and deliver measurable impact uniting connected expertise and advanced technology platforms into a single advisory solution designed to deliver greater impact for clients and the patients they serve.
Inizio Ignite operates as part of Inizio’s broader global commercialization platform, enabling clients to seamlessly access deep, cross-functional expertise across the entire product lifecycle. With more than 10,500 experts in over 50 countries, Inizio brings together scientific, medical, commercial, analytics, and technology capabilities to help clients solve complex challenges in a flexible, client-centred way – from strategy through execution.
Focused exclusively on life sciences and healthcare, Inizio Ignite integrates Inizio’s former Advisory capabilities to create one of the largest and most specialized advisory partners in the sector. With more than 1,000 experts, including 100 PhD, PharmD, and MDs across more than 50 countries, Inizio Ignite advises clients across more than 20 therapy and disease areas and has partnered on 1,100 assets with all top 20 pharmaceutical companies. Across the product lifecycle, from early development through post-launch, Inizio Ignite supports data-driven portfolio and launch strategies, embeds advanced analytics, and translates insight into execution – delivering Intelligent Commercialization™ as part of Inizio’s end-to-end platform.
Remco op den Kelder, Global President of Inizio Ignite, said:
“By uniting our teams, we’re creating something new – an integrated partner bringing together the insight, strategy, and transformation support that pharma companies need to win in today’s market. This evolution represents a meaningful shift in how we serve our clients, delivering clearer answers, stronger guidance, and faster impact for the patients who rely on them.”
“With a seamlessly connected team, clients benefit from deeper expertise and broader capabilities at every stage of their journey. This transformation strengthens our ability to drive innovation at scale, pairing clarity and precision with the speed required to turn strategy into real-world impact. It positions us to advance the next generation of treatments and to help shape the future of human health.”
Find out more about Inizio Ignite and its solutions here.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Biosimilars: Bringing patients into the conversation
Published in eyeforpharma January 2017 by Mariel Metcalfe
Access and elimination: the future of DAAs in hepatitis C
Published in Pharmaphorum January 2017
EphMRA One Day Meeting
We are delighted to be attending and presenting a paper at the EphMRA one day meeting on Tuesday 21st February, in London
Video: Segmentation research
Why would a pharma company want to carry out a segmentation study? What are some of the challenges? Head of Business Analytics Tom Nolte and Associate Director Dr Marianne Jaeger...
Pharmaceutical Market Research Conference 2017
We are delighted to be exhibiting and presenting a paper at the Pharmaceutical Market Research Conference 1-2 February in Parsippany, NJ.
Shifting perceptions of the use of probiotics in IBS Management
Our client was planning to launch an over-the-counter (OTC) probiotics product for the purposes of improving IBS management and wanted to understand current perceptions, practices and usage amoungst a range...
Nutraceuticals in India: A Challenging Opportunity
Published in eyeforpharma December 2016 by Marc Yates
Research Partnership makes annual donation to Forever Projects
Research Partnership has made a seasonal donation of US$5,000 to our chosen charity, Forever Projects
A Bitter Pill?
The ideal route of admin isn’t clear cut in the global marketplace
Understanding the chronic disease patient journey in emerging markets
In this paper, we will explore the chronic disease patient journey in emerging markets and provide you with the insights you require to identify the key inflection points in these...